These results confirm that PRMT1 knockdown effectively enhances the efficacy and durability of EGFR and KRASG12C drugs in lung cancer xenograft models, demonstrating that the robust activity of the PRMT1-targeting strategy to eliminate persistence is translatable from in vitro to in vivo. This evidence concerns the gene PRMT1 and lung carcinoma.